The New England Journal of Medicine has published a detailed analysis of Genentech’s positive results from the Phase III REGENCY study of Gazyva® (Obinutuzumab) for people with active lupus nephritis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback